Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.74 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.74 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.71 |
| ▸ | USP7 | Q93009 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | STAT3 | P40763 | 1/20 | 0.71 |
| ▸ | CCR6 | P51684 | 1/20 | 0.62 |
| ▸ | RORC | P51449 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10212158 | 1.00 | NOS2 (0.74) | NOS2KEAP1MBOAT4CYP3A4CYP2C19 | |
| SCHEMBL706403 | 1.00 | NOS2 (0.74) | NOS2KEAP1MBOAT4CYP3A4CYP2C19 | |
| SCHEMBL23553394 | 1.00 | NOS2 (0.74) | NOS2KEAP1MBOAT4CYP3A4CYP2C19 | |
| SCHEMBL14931249 | 1.00 | NOS2 (0.74) | NOS2KEAP1MBOAT4CYP3A4CYP2C19 | |
| SCHEMBL13666203 | 0.92 | MBOAT4 (0.71) | NOS2KEAP1MBOAT4CYP3A4CYP2C19 | |
| SCHEMBL14931397 | 0.92 | MBOAT4 (0.73) | NOS2KEAP1MBOAT4CYP3A4CYP2C19 | |
| SCHEMBL1036288 | 0.92 | MBOAT4 (0.73) | NOS2KEAP1MBOAT4CYP3A4CYP2C19 | |
| SCHEMBL1036286 | 0.92 | MBOAT4 (0.73) | NOS2KEAP1MBOAT4CYP3A4CYP2C19 | |
| SCHEMBL21882544 | 0.92 | NOS2 (0.69) | NOS2KEAP1MBOAT4CYP3A4CYP2C19 | |
| SCHEMBL10212066 | 0.92 | MBOAT4 (0.73) | NOS2KEAP1MBOAT4CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353813-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | Reata Pharmaceuticals Holdings, LLC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12358866-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | Reata Pharmaceuticals Holdings, LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240317676-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | Reata Pharmaceuticals Holdings, LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-11919838-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | Reata Pharmaceuticals Holdings, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220024862-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11091430-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 | REATA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200239410-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-10556858-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190119202-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| EP-2276493-B1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS INC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-10093614-B2 | Antioxidant Inflamation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180002277-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9670147-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150376121-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-9102681-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130317007-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8124799-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093614-B2 | Antioxidant Inflamation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | ALOX15, ALOX12, HMOX1 | NOS2 77/4885KEAP1 44/4885MBOAT4 865/4885 |
| US-20240317676-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-12358866-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-20180002277-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-11919838-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-20220024862-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-20200239410-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-20150376121-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-20130317007-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-11091430-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-20190119202-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-20100048892-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-10556858-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
| US-20250353813-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | NOS2 41/4885KEAP1 59/4885MBOAT4 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.